AbbVie Inc.

118.19+0.6500+0.55%Vol 4.40M1Y Perf 20.78%
Jul 23rd, 2021 16:02 DELAYED
BID118.05 ASK118.11
Open117.98 Previous Close117.54
Pre-Market- After-Market117.95
 - -  -0.24 -0.20%
Target Price
120.62 
Analyst Rating
Moderate Buy 1.64
Potential %
2.06 
Finscreener Ranking
★+     43.17
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     45.59
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     49.02
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★+     41.79
Market Cap208.75B 
Earnings Rating
Neutral
Price Range Ratio 52W %
98.79 
Earnings Date
30th Jul 2021

Today's Price Range

117.57118.67

52W Range

79.11118.67

5 Year PE Ratio Range

11.9038.30

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.59%
1 Month
3.01%
3 Months
6.11%
6 Months
6.61%
1 Year
20.78%
3 Years
29.11%
5 Years
85.22%
10 Years
-

TickerPriceChg.Chg.%
ABBV118.190.65000.55
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
0.60
0.80
0.84
6.24
2.70
Leverage Ratio 11.20
ProfitabilityValueIndustryS&P 500US Markets
64.80
13.30
29.50
17.70
15.15
RevenueValueIndustryS&P 500US Markets
39.77B
22.52
11.13
11.63
DividendsValueIndustryS&P 500US Markets
4.51
5.20
18.22
18.95
Payout ratio173.00
Earnings HistoryEstimateReportedSurprise %
Q01 20212.772.956.50
Q04 20202.852.922.46
Q03 20202.752.832.91
Q02 20202.242.344.46
Q01 20202.272.426.61
Q04 20192.202.210.45
Q03 20192.292.331.75
Q02 20192.212.262.26
Earnings Per EndEstimateRevision %Trend
6/2021 QR3.07-0.65Negative
9/2021 QR3.230.31Positive
12/2021 FY12.620.88Positive
12/2022 FY14.020.72Positive
Next Report Date30th Jul 2021
Estimated EPS Next Report3.11
Estimates Count6
EPS Growth Next 5 Years %5.30
Volume Overview
Volume4.40M
Shares Outstanding1.77B
Trades Count48.05K
Dollar Volume911.93M
Avg. Volume6.87M
Avg. Weekly Volume5.23M
Avg. Monthly Volume6.01M
Avg. Quarterly Volume6.36M

AbbVie Inc. (NYSE: ABBV) stock closed at 118.19 per share at the end of the most recent trading day (a 0.55% change compared to the prior day closing price) with a volume of 4.41M shares and market capitalization of 208.75B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 47000 people. AbbVie Inc. CEO is Richard A. Gonzalez.

The one-year performance of AbbVie Inc. stock is 20.78%, while year-to-date (YTD) performance is 10.3%. ABBV stock has a five-year performance of 85.22%. Its 52-week range is between 79.11 and 118.67, which gives ABBV stock a 52-week price range ratio of 98.79%

AbbVie Inc. currently has a PE ratio of 42.40, a price-to-book (PB) ratio of 15.14, a price-to-sale (PS) ratio of 5.13, a price to cashflow ratio of 11.00, a PEG ratio of 2.32, a ROA of 4.12%, a ROC of 8.29% and a ROE of 175.15%. The company’s profit margin is 15.15%, its EBITDA margin is 29.50%, and its revenue ttm is $39.77 Billion , which makes it $22.52 revenue per share.

Of the last four earnings reports from AbbVie Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.11 for the next earnings report. AbbVie Inc.’s next earnings report date is 30th Jul 2021.

The consensus rating of Wall Street analysts for AbbVie Inc. is Moderate Buy (1.64), with a target price of $120.62, which is +2.06% compared to the current price. The earnings rating for AbbVie Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AbbVie Inc. has a dividend yield of 4.51% with a dividend per share of $5.20 and a payout ratio of 173.00%.

AbbVie Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.76, ATR14 : 1.71, CCI20 : 103.62, Chaikin Money Flow : 0.30, MACD : 0.83, Money Flow Index : 73.64, ROC : 1.23, RSI : 61.49, STOCH (14,3) : 90.26, STOCH RSI : 1.00, UO : 57.26, Williams %R : -9.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AbbVie Inc. in the last 12-months were: Azita Saleki-Gerhardt (Option Excercise at a value of $3 152 428), Azita Saleki-Gerhardt (Sold 109 146 shares of value $12 265 108 ), Carlos Alban (Option Excercise at a value of $4 155 980), Carlos Alban (Sold 115 830 shares of value $11 583 000 ), Carrie C. Strom (Option Excercise at a value of $173 176), Carrie C. Strom (Sold 4 184 shares of value $470 282 ), Elaine K. Sorg (Option Excercise at a value of $1 813 052), Elaine K. Sorg (Sold 28 635 shares of value $3 031 374 ), Henry O. Gosebruch (Sold 40 000 shares of value $3 975 046 ), Jeffrey Ryan Stewart (Option Excercise at a value of $2 600 822), Jeffrey Ryan Stewart (Sold 64 353 shares of value $6 806 475 ), Michael Severino (Sold 90 679 shares of value $8 488 461 ), Richard A. Gonzalez (Option Excercise at a value of $20 422 257), Richard A. Gonzalez (Sold 401 717 shares of value $40 913 456 ), Timothy J. Richmond (Option Excercise at a value of $2 673 325), Timothy J. Richmond (Sold 71 504 shares of value $7 577 990 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (64.29 %)
8 (66.67 %)
6 (50.00 %)
Moderate Buy
1 (7.14 %)
1 (8.33 %)
0 (0.00 %)
Hold
4 (28.57 %)
3 (25.00 %)
6 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.64
Moderate Buy
1.58
Moderate Buy
2.00

AbbVie Inc.

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

CEO: Richard A. Gonzalez

Telephone: +1 847 932-7900

Address: 1 North Waukegan Road, North Chicago 60064-6400, IL, US

Number of employees: 47 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

53%47%

Bearish Bullish

56%44%

News

Stocktwits